NEW YORK, NY / ACCESSWIRE / May 1, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Corcept Therapeutics Incorporated (CORT)
Class Period: August 2, 2017 to February 5, 2019
Lead Plaintiff Deadline: May 13, 2019
The lawsuit alleges that Corcept Therapeutics Incorporated made materially false and/or misleading statements and/or failed to disclose that: (1) the Company had improperly paid doctors to promote its drug Korlym; (2) the Company aggressively promoted Korlym for off-label uses; (3) the Company's sole specialty pharmacy was a related party; (4) the Company artificially inflated its revenue and sales using illicit sales practices through a related party; (5) such practices are reasonably likely to lead to regulatory scrutiny; and (6) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Get additional information about the CORT lawsuit: http://www.kleinstocklaw.com/pslra-1/corcept-therapeutics-incorporated-loss-submission-form?id=1343&from=1
Bridgepoint Education Inc. (BPI)
Class Period: March 8, 2016 to March 7, 2019
Lead Plaintiff Deadline: May 10, 2019
The complaint alleges that throughout the class period Bridgepoint Education Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Bridgepoint's processes for recording revenue for its FTG program were inaccurate; (ii) Bridgepoint maintained deficient internal controls; (iii) due to the foregoing deficiencies, Bridgepoint was prone to and did commit material accounting errors related to revenue, provision for bad debts, accounts receivable and deferred revenue, which resulted in the overstatement of revenue and expenses; and (iv) as a result, Bridgepoint's public statements were materially false and misleading at all relevant times.
Get additional information about the BPI lawsuit: http://www.kleinstocklaw.com/pslra-1/bridgepoint-education-inc-loss-submission-form?id=1343&from=1
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Class Period: November 14, 2016 to February 28, 2019
Lead Plaintiff Deadline: May 13, 2019
Corbus Pharmaceuticals Holdings, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Corbus improperly changed the primary efficacy endpoint for the clinical study of its drug candidate, Lenabasum, after the results were unblinded to Corbus; (2) Corbus reported a one-sided p value, not the traditional two-sided p value normally reported in clinical trials, in an effort to conceal the fact that the study results did not have statistical significance; and (3) as a result, Corbus' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
Get additional information about the CRBP lawsuit: http://www.kleinstocklaw.com/pslra-1/corbus-pharmaceutical-holdings-inc-loss-submission-form?id=1343&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: The Klein Law Firm
View source version on accesswire.com: